The Genome's Big Data Problem
By Joseph Cox,
Mother Board
| 06. 04. 2014
Untitled Document
Medicine will be revolutionised in the 21st century, thanks largely to our increasing understanding and collection of genetic data.
Genetic data is information pertaining to part or all of your genome: the DNA structure that makes you you. This is translated into a massive string of letters—approximately six billion characters in length—that can reveal all sorts of things about you.
Thanks to the rise of genome sequencing, prescription medicines could end up being tailored towards individuals, increasing the drugs' effectiveness and minimising their side effects. Treatments could be developed for previously resilient diseases thanks to greater information available for research. It could even be possible to predict how predisposed infants are to various conditions as they grow up.
One program already using genetic data is the Personal Genome Project (PGP), an open call to those who wish to contribute to scientific research. If someone decides to participate in the project, they naturally have to sign a consent form—but it's not as easy as blindly clicking ‘I have read and agree to the Terms and Conditions.’ The New York Times reported that participants need to pass a test...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...